Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

A daily pill, Kisqali is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor that prevents cancer cells from dividing and growing. This kind of drug is taken with an aromatase inhibitor ...

The FDA recently expanded the approval of the breast cancer drug Kisqali to treat patients with earlier stages of the disease. Thousands of women diagnosed with early-stage breast cancer will have ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug be used in combination ... the late-stage NATALEE trial. Adjuvant Kisqali plus endocrine therapy reduced the ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...

Kisqali was approved as a treatment for early breast cancer by the U.S. Food and Drug Administration (FDA) in September 20245. Regulatory reviews for Kisqali as an EBC treatment are ongoing ...

Novartis' strong breast cancer portfolio has the top drug Kisqali, which has put up a spectacular performance. The Zacks Consensus Estimate for Sanofi’s earnings has risen from $4.21 to $4.25 ...

LaShae Rolle shares her journey of being diagnosed with a rare breast cancer at the age of 26, making her a part of the less ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...